DV
Dividend Vision

INBX — Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. (INBX)

Total return is 658.1% over the past 2.2 years, 606.6 points ahead of SPY at 51.5%. Its deepest 1-year drawdown was 44.1%.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing biologic therapeutics targeting life-threatening conditions, with lead candidates including INBRX-109 for chondrosarcoma and INBRX-106 for various solid tumors currently in early-stage clinical trials. The company does not currently distribute dividends. Inhibrx appeals to investors seeking exposure to early-stage biotech development rather than current income generation.

INBX key facts

Asset type
Stock
Asset class
Equity
Inception date
05/29/2024
Last close
$88.37
Market cap
$1,300,599,680
Average volume
268300.0
Ex-dividend date
05/30/2024
Payment date
06/20/2024
Beta
3.521
Payout ratio
0.0
Forward P/E
0.0
EPS
$-8.12